从可植入的阿尔金酸盐-索鲁普拉斯复合器件中冷却触发的切莱科西布释放
Romario Lobban1, Michael Carroll2, Victoria Vest1
1Department of Mechanical Engineering, Vanderbilt University, 2201 West End Avenue, Nashville, Tennessee 37235, United States.
ACS biomaterials science & engineering
|August 25, 2025
概括
局部冷却可以触发可植入器件中的非类固醇抗炎药物 (NSAIDs) 的释放,为阿片类药物提供更安全的,随需的止痛替代品.
科学领域:
- 生物材料科学
- 提供药物
- 治疗疼痛
背景情况:
- 基于阿片类药物的疼痛治疗存在严重的成风险,
- 非类固醇抗炎药 (NSAID) 提供非上性疼痛缓解,但需要改进局部输送方法.
- 目前的外部刺激释放药物系统缺乏口服的便利性.
研究的目的:
- 开发和评估一种新的冷却触发药物输送系统,用于按需释放NSAID.
- 研究使用局部冷却作为治疗疼痛的安全和方便刺激的可行性.
- 通过轻度冷却激活可控制NSAID释放的可植入装置.
主要方法:
- 使用物理交叉连接的热敏聚合物水凝,在降温到低于其较低的临界溶液温度 (LCST) 时呈现凝到溶液的转变.
- 将NSAID (Celecoxib) 纳入水凝,并与非热敏膜材料结合,以创建可植入的存储器.
- 在模拟体液,细胞培养,扩张组织和活体动物伤口模型中特征冷却触发释放.
主要成果:
- 通过冷却引发的NSAIDs从基于水凝的植入器件中释放.
- 在轻度冷却 (29°C) 时,药物释放率增加了约40倍.
- 在活体动物模型中支持多个触发释放周期和有效性的设备功能.
结论:
- 局部冷却是一种可行且方便的激发剂,
- 通过冷却引发的NSAID释放为全身阿片类药物治疗提供了一个有希望的,非成的替代方案.
- 这项技术使患者能够使用熟悉的方法 (冰袋) 缓解疼痛.
相关概念视频
01:19Modified-Release Drug Delivery Systems: Overview
243
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
243
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
265
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
265
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
186
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
186
01:24Modified-Release Drug Delivery Systems: Site-Targeted
167
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
167
01:26Oral Drug Delivery Systems: Continuous-Release Systems
323
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
323
01:11Oral Drug Delivery Systems: Delayed-Release Systems
229
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
229